Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study.
Saved in:
| Title: | Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study. |
|---|---|
| Authors: | Onishi A; Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, 54, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. telonishi@gmail.com., Tanaka M; Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, 54, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan., Fujii T; Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, 54, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.; Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan., Murata K; Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, 54, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.; Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan., Murakami K; Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Hashimoto M; Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan., Watanabe R; Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan., Nozaki Y; Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan., Ashida C; Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan., Yamamoto W; Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan., Yamada H; Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan., Sendo S; Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan., Ebina K; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.; Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, Osaka, Japan., Makino H; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan., Son Y; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan., Wada Y; Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, Japan., Hata K; Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, Japan., Matsuda S; Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan., Morinobu A; Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan. |
| Source: | Arthritis research & therapy [Arthritis Res Ther] 2025 Mar 07; Vol. 27 (1), pp. 52. Date of Electronic Publication: 2025 Mar 07. |
| Publication Type: | Journal Article; Multicenter Study; Comparative Study |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101154438 Publication Model: Electronic Cited Medium: Internet ISSN: 1478-6362 (Electronic) Linking ISSN: 14786354 NLM ISO Abbreviation: Arthritis Res Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1478-6362 |
|---|---|
| DOI: | 10.1186/s13075-025-03514-x |
